This work provides a basis for continued development of inhibitors against Plasmodium M1 alanyl aminopeptidase in an era when new therapeutics with novel mechanisms of action are urgently needed to combat widespread emergence of malaria parasite drug resistance. The gene discussed is ANPEP; the disease is malaria.